• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

Akebia Therapeutics (AKBA)

Common Shares
Sell: $1.33|Buy: $1.36|Change: 0.06 (-4.35%)

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

Address

245 First Street
Suite 1100
Cambridge
MA
USA
02142

Telephone

+1 617 8712098

Website

https://www.akebia.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Akebia Therapeutics Inc Fourth Quarter Earnings Conference Call for 20262027-02-26T08:00:00
Akebia Therapeutics Inc Fourth Quarter Earnings Results for 20262027-02-26T00:00:00
Akebia Therapeutics Inc Annual Report for 20262027-02-26T00:00:00
Akebia Therapeutics Inc Third Quarter Earnings Conference Call for 20262026-11-10T08:00:00
Akebia Therapeutics Inc Third Quarter Earnings Results for 20262026-11-10T00:00:00
Akebia Therapeutics Inc Second Quarter Earnings Conference Call for 20262026-08-07T08:00:00
Akebia Therapeutics Inc Second Quarter Earnings Results for 20262026-08-07T00:00:00
Akebia Therapeutics Inc Annual General Meeting for 20262026-06-10T10:00:00
Akebia Therapeutics Inc First Quarter Earnings Conference Call for 20262026-05-08T08:00:00
Akebia Therapeutics Inc First Quarter Earnings Results for 20262026-05-08T00:00:00
Akebia Therapeutics Virtual R&D Day2026-04-02T10:00:00

Previous key dates

NameKey Date
Akebia Therapeutics Virtual R&D Day2026-04-02T10:00:00
Leerink Global Healthcare Conference2026-03-09T08:00:00
Akebia Therapeutics Inc Fourth Quarter Earnings Conference Call for 20252026-02-26T08:00:00
Akebia Therapeutics Inc Fourth Quarter Earnings Result for 20252026-02-26T00:00:00
Akebia Therapeutics Inc Annual Report for 20252026-02-26T00:00:00
Guggenheim Emerging Outlook: Biotech Summit 20262026-02-12T09:30:00
Piper Sandler 37(th) Annual Healthcare Conference2025-12-02T16:30:00
Jefferies Global Healthcare Conference2025-11-17T07:00:00
Guggenheim Healthcare Innovation Conference2025-11-10T15:00:00
Akebia Therapeutics Inc Third Quarter Earnings Conference Call for 20252025-11-10T08:00:00
Akebia Therapeutics Inc Third Quarter Earnings Results for 20252025-11-10T00:00:00
H.C. Wainwright Global Investment Conference2025-09-08T12:00:00
2025 Wells Fargo Healthcare Conference2025-09-04T08:00:00
Canaccord Genuity’s 45th Annual Growth Conference2025-08-13T13:30:00
Akebia Therapeutics Inc Second Quarter Earnings Conference Call for 20252025-08-07T08:00:00
Akebia Therapeutics Inc Second Quarter Earnings Results for 20252025-08-07T00:00:00
H.C. Wainwright 4(th) Annual Kidney Virtual Conference2025-07-14T10:00:00
Akebia Therapeutics Inc Annual General Meeting for 20252025-06-10T10:00:00
Jefferies Global Healthcare Conference2025-06-05T08:45:00
H.C. Wainwright 3rd Annual BioConnect Investor Conference2025-05-20T14:30:00
Akebia Therapeutics Inc First Quarter Earnings Conference Call for 20252025-05-08T08:00:00
Akebia Therapeutics Inc First Quarter Earnings Result for 20252025-05-08T00:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2026 AJ Bell. All rights reserved.